分子建模和实验验证确定了一种新的毒素菌抑制剂
Oluyomi Stephen Adeyemi1, Titilayo Johnson2, Tobiloba Maduakolam-Aniobi3
1Medicinal Biochemistry and Toxicology Laboratory, Department of Biochemistry, Bowen University, Iwo, 232101, Osun State, Nigeria; Laboratory of Sustainable Animal Environment Systems, Graduate School of Agricultural Sciences, Tohoku University, Japan.
Computers in biology and medicine
|October 8, 2024
概括
研究人员确定了基于伊米达的新型化合物作为毒素菌的潜在治疗方法. 化合物C5通过抑制复制和生长,对Toxoplasma gondii表现出显著的抗寄生虫活性,提供了一个有前途的替代治疗选择.
科学领域:
- 寄生虫学的寄生虫学
- 计算化学计算化学
- 药物发现 药物发现 药物发现
背景情况:
- 由Toxoplasma gondii引起的毒素,是一种流行的寄生虫疾病,影响了人类人口的很大一部分.
- 迫切需要有效的治疗方法,需要探索新的治疗策略来对抗毒素菌.
研究的目的:
- 通过计算和实验方法识别新型的毒素菌治疗抑制剂.
- 评估已识别的化合物的抗寄生虫活性和宿主毒性,以对抗Toxoplasma gondii.
主要方法:
- 通过分子对接,对3000种天然化合物的T. gondii依赖的蛋白激酶1 (TgCDPK1) 进行虚拟选.
- 在中毒性和选择化合物的ADME分析.
- 对T. gondii的9种有前途的化合物的体外实验验证,包括剂量反应测定和宿主毒性评估.
主要成果:
- 四种化合物 (C4,C5,C6,C8) 显示了剂量依赖的抗T. gondii活性,EC50值在3.3至120.2μg/mL之间.
- 基于伊米达的天然产品化合物C5表现出显著的可逆抗寄生虫作用,主要是通过阻碍寄生虫的复制和生长,其选择性指数为1.8.
- 分子动力学模拟表明了C5-TgCDPK1复合物的稳定性.
结论:
- 基于伊米达的化合物,特别是C5,显示出作为抗毒素菌的新疗法药物的显著潜力.
- 这些发现支持进一步研究以开发替代抗寄生虫药物的意达衍生物.
更多相关视频
相关概念视频
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...